Fujitsu Leverages Artificial Intelligence for Treatment of Diabetes during Pregnancy
- New collaboration with the Finnish CleverHealth Network ecosystem enables development of an AI-based service with more effective monitoring and treatment for mothers suffering from gestational diabetes
- Fujitsu delivers data integration and modelling services in addition to a user interface to clearly visualize the data for health care professionals
- Machine learning also analyzes health and lifestyle data to provide guidance and treatment tailored to each patient’s individual needs and risk profile
Notes to editors
1The CleverHealth Network development projects bring together the health technology competence of Finnish enterprises, leading experts in health care and high-quality health data collected by HUS. The main partners in the gestational diabetes project are HUS, Elisa, Fujitsu, Aalto University and the University of Helsinki, with funding provided by Business Finland.
Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 155,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE: 6702) reported consolidated revenues of 4.5 trillion yen (US$40 billion) for the fiscal year ended March 31, 2017. For more information, please see http://www.fujitsu.com.
All other company or product names mentioned herein are trademarks or registered trademarks of their respective owners. Information provided in this press release is accurate at time of publication and is subject to change without advance notice.
Date: 11 April, 2018